PDC and primary biliary cholangitis: At baseline, PBC patients had significantly higher anti-PDC-E2 serum levels (mean 2.9 ± 1.9 AU vs 2.0 ± 1.6 AU; p = 0.044), anti-PDC-E2 avidity (68% ± 21% vs 61% ± 24%; p = 0.014) and IIF-AMA (median 1/1280 (1/40–1/20,480) vs 1/320 (1/40–1/20,480); p < 0.001) compared to BN/AMA-positive individuals, confirming our previous results [16].